Hewitt covers the Healthcare sector, focusing on stocks such as Ligand Pharma, MaxCyte, and BioLife Solutions. According to TipRanks, Hewitt has an average return of 3.5% and a 47.72% success rate on recommended stocks.
Currently, the analyst consensus on MaxCyte is a Strong Buy with an average price target of $4.00.
Based on MaxCyte’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $9.65 million and a GAAP net loss of $4.75 million. In comparison, last year the company earned a revenue of $10.39 million and had a GAAP net loss of $10.26 million
